All Stories

  1. Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillary and Distal Myopathies
  2. Duchenne muscular dystrophy: diagnosis and perspective of treatment
  3. Editorial: Sleep disorders in neuromuscular diseases: treatable conditions: the evolving scenario of sleep in neuromuscular disorders
  4. A severe case of MG rescued after Covid-19 infection from ICU
  5. The Multifaceted Cause of Lipid Storage Myopathies, Genetics, and Treatment
  6. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29–30 October 2021
  7. This illustrates the use of newborn screening in several neuromuscular disorders
  8. This study aims to analyze the coping strategies in a sample of people with several types of NMD
  9. Indications and contraindications of traveling at high altitude
  10. Newly approved drugs for neuromuscular disease.
  11. How to treat dystrophinopathy
  12. A review of avalglucosidase alpha, a therapy admitted by FDA and European regulatory agencies
  13. Differential Dysferlin Expression in Rat Muscle
  14. A summary of advances of the MDPI Journal Muscles
  15. News and views on Duchenne, Becker and carriers of muscular dystrophy
  16. Limb–Girdle Muscular Dystrophy D2 TNPO3-Related: A Quality of Life Study
  17. A collection of articles dedicated to energy and metabolism
  18. History of international connections of myology in Europe
  19. ALL ICNMD Congresses in details
  20. The different clinical picture of two siblings affected by rare neutral lipid storage disease
  21. Myofibrillar myopathies are due to mutations in Z-line proteins
  22. Explains the history and status of art in a myopathy frequent in Tunisia
  23. Effects of Triheptanoin on Mitochondrial Respiration and Glycolysis in Cultured Fibroblasts from Neutral Lipid Storage Disease Type M (NLSD-M) Patients
  24. Risk of stroke in different populations and relatively high altitude habitat
  25. A full account of metabolic myopathy,clinical signs, diagnostic odissea
  26. Distinct Phenotypic and microRNA Expression in X-Linked Charcot–Marie–Tooth Correlated with a Novel Mutation in the GJB1 Gene
  27. Muscles—A New Open Access Journal
  28. A limb-girdle dystrophy due to transportin-3 a nuclear carrier of the HIV virus
  29. Governance of Access in Biobanking: The Case of Telethon Network of Genetic Biobanks
  30. A childhood case of bag-3 myofibrillar myopathy heart transplanted presenting pancreatic tumor
  31. In a patient with limb asymmetry calsequestrin mutation was identified
  32. NEW GENES AND DISEASES
  33. LIMB-girdle muscular dystrophy D2 and cytokines: A link to HTV1 resistance
  34. LGMD
  35. An updated review on the role of prescribed exercise in the management of Amyotrophic lateral sclerosis
  36. Recurrent N209* ABHD5 mutation in two unreported families with Chanarin Dorfman Syndrome
  37. Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium
  38. ETF dehydrogenase advances in molecular genetics and impact on treatment
  39. Morphological study of TNPO3 and SRSF1 interaction during myogenesis by combining confocal, structured illumination and electron microscopy analysis
  40. Circulating miR-206 as a Biomarker for Patients Affected by Severe Limb Girdle Muscle Dystrophies
  41. Recommendation about going to altitude for people
  42. Large genotype–phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis
  43. Assessing diagnosis and managing respiratory and cardiac complications of sarcoglycanopathy
  44. Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1
  45. Diagnostic challenges in metabolic myopathies
  46. MiRNAs, Myostatin, and Muscle MRI Imaging as Biomarkers of Clinical Features in Becker Muscular Dystrophy
  47. A 5-year clinical follow-up study from the Italian National Registry for FSHD
  48. Transportin 3 (TNPO3) and related proteins in limb girdle muscular dystrophy D2 muscle biopsies: A morphological study and pathogenetic hypothesis
  49. Neuromuscular diseases and Covid-19: Advices from scientific societies and early observations in Italy
  50. Phenotypic Variability Among Patients With D4Z4 Reduced Allele Facioscapulohumeral Muscular Dystrophy
  51. MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients
  52. MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy
  53. Interpretation of the Epigenetic Signature of Facioscapulohumeral Muscular Dystrophy in Light of Genotype-Phenotype Studies
  54. Correlation between ETFDH mutations and dysregulation of serum myomiRs in MADD patients
  55. Can miR-34a be suitable for monitoring sensorineural hearing loss in patients with mitochondrial disease? A case series
  56. European Federation of the Neurological Societies guidelines on the diagnostic approach to paucisymptomatic or asymptomatic hyperCKemia
  57. MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy
  58. Review: Danon disease: Review of natural history and recent advances
  59. P.88Lipid storage myopathies due to ETFDH and PNPLA2 mutations: MRI and microRNA role as biomarkers
  60. P.28Tracking cognitive changes in DM1 in a 5 year follow-up study
  61. Update on polyglucosan storage diseases
  62. This review explains the revised nomenclature of limb-girdle muscular dystrophies.
  63. MyomiRNAs Dysregulation in ALS Rehabilitation
  64. This is a top review on muscle lipid metabolic disorders
  65. Advances in imaging of brain abnormalities in neuromuscular disease
  66. A new family with transportinopathy: increased clinical heterogeneity
  67. Authors’ reply
  68. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol
  69. Clinical and genetic characterization of an Italian family with slow-channel syndrome
  70. Regulation of ER-mitochondria contacts by Parkin via Mfn2
  71. Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency
  72. Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients
  73. LGMD AUTOSOMAL RESSESSIVE AND DOMINANT
  74. METABOLIC MYOPATHIES I
  75. Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study
  76. ERRATUM: Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study
  77. The role of activated microglia and its polarization is presented in CNS disorders
  78. An update on diagnostic options and considerations in limb-girdle dystrophies
  79. Pathogenetic mechanism of limb girdle muscle diseases: an integrated approach
  80. MicroRNAs are appropriate in mitochondrial related hearing loss? Answer to the skepticism
  81. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease
  82. A mobile app for patients with Pompe disease and its possible clinical applications
  83. Enzyme replacement therapy for the treatment of Pompe disease
  84. Interpreting Genetic Variants in Titin in Patients With Muscle Disorders
  85. Role of microRNAs in lipid storage myopathies. (P3.458)
  86. Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study
  87. Remodel mitochondria and get energized
  88. Hearing impairment in MELAS: new prospective in clinical use of microRNA, a systematic review
  89. This illustrates a series of neuromuscular and metabolic disorders with patients clinical feature.
  90. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
  91. Emery-Dreifuss Muscular Dystrophy Type 4
  92. Danon Disease
  93. Scapuloperoneal Myopathy
  94. Amyotrophic Lateral Sclerosis
  95. Clinical variability in myotonic dystrophy type 1: a five-categories disease classification fits clinical but not brain complexity
  96. Report on nationwide Italian collaborative network for muscle glycogen storage disorders
  97. Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration
  98. Limb girdle muscular dystrophies: clinical-genetical diagnostic update and prospects for therapy
  99. ATP1A3 mutant patient with alternating hemiplegia of childhood and brain spectroscopic abnormalities
  100. Aberrant Compartment Formation by HSPB2 Mislocalizes Lamin A and Compromises Nuclear Integrity and Function
  101. Revisiting mitochondrial ocular myopathies: a study from the Italian Network
  102. study of biopsies in late onset pompe cases
  103. Erratum to: Muscle MRI in neutral lipid storage disease (NLSD)
  104. Muscle MRI in neutral lipid storage disease (NLSD)
  105. Neutral Lipid Storage Diseases: clinical/genetic features and natural history in a large cohort of Italian patients
  106. Presents an expert consensus at the European level of results of ERT in late-onset Pompe disease
  107. Generation of induced Pluripotent Stem Cells as disease modelling of NLSDM
  108. Corrigendum to “Response to: Mitochondrial neuropathy affects peripheral and cranial nerves and is primary or secondary or both” [Neuromuscular Disorders 26/8 (2016) 549]
  109. Cerebral venous thrombosis at high altitude: A systematic review
  110. Elevated Expression of Moesin in Muscular Dystrophies
  111. Metabolites-mitochondria-macrophages (MMM): new therapeutic avenues for inflammation and muscle atrophy
  112. Micro-RNA expression in muscle and fiber morphometry in myotonic dystrophy type 1
  113. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I
  114. The role of transmission electron microscopy in vacuole-associated myopathies
  115. Study of TFEB and experiments on DAnon and Pompe fibroblasts.
  116. Heterogeneous Phenotypes in Lipid Storage Myopathy Due to ETFDH Gene Mutations
  117. Coverage of pathogenesis and clinical features of alphabet,gamma,delta sarcoglycanopathies.
  118. Study of a cohort of myotonic dystrophy patients with anew FES protocol and aerobic exercise
  119. The italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis
  120. Review of the state of the art in dysferlin deficient patients.
  121. NMR voxel-based morphometry and functional analysis as neural correlates of neuropsychological dysfunction in DM1
  122. Functional studied in Becker muscular dystrophy.
  123. MicroRNA signatures predict dysregulated vitamin D receptor and calcium pathways status in limb girdle muscle dystrophies (LGMD) 2A/2B
  124. Response to: Mitochondrial neuropathy affects peripheral and cranial nerves and is primary or secondary or both
  125. Lipolysis and lipophagy in lipid storage myopathies
  126. The genetic basis of undiagnosed muscular dystrophies and myopathies
  127. Identification of an intragenic deletion in the SGCB gene through a re-evaluation of negative next generation sequencing results
  128. A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes
  129. Next generation sequencing detection of late onset pompe disease
  130. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study
  131. “Mitochondrial neuropathies”: A survey from the large cohort of the Italian Network
  132. Challenges and progress in the diagnosis of Congenital Muscular Dystrophies
  133. Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1
  134. Neuromuscular disorders of autoimmune or endocrinological causes are presented.
  135. The most interesting result is that there is a high clinical variability in children. with FSHD1
  136. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS
  137. Diagnosis and discovery in limb-girdle muscular dystrophy
  138. LGMD phenotype due to a new gene and dysferlinopathy investigated by next-generation sequencing
  139. Reply
  140. Erratum to: Redefining phenotypes associated with mitochondrial DNA single deletion
  141. Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy
  142. Are white matters changes in dm1 brain related to anosognosia?
  143. Biomarkers in skeletal muscle rehabilitation in myotonic dystrophy
  144. Familial polyglucosan body myopathy: A clinical spectrum
  145. Investigation of regulatory factors in Lipid Storage Myopathies (LSM) with triglyceride accumulation
  146. Large screening of patients diagnosed as limb girdle muscular dystrophy or congenital myopathy using Motorplex
  147. Longitudinal functional measures in Becker muscular dystrophy: Implications for clinical trials and Duchenne exon skipping outcomes
  148. GYG1gene mutations in a family with polyglucosan body myopathy
  149. [An] enumeration shall be made…
  150. TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy
  151. This paper explains the development of deflazacort now available as Defla from PTC in US and Canada
  152. 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26–28 September 2014
  153. Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations
  154. Incomplete penetrance in limb-girdle muscular dystrophy type 1F
  155. Novel missense mutations in PNPLA2 causing late onset and clinical heterogeneity of neutral lipid storage disease with myopathy in three siblings
  156. Protein and genetic diagnosis of limb girdle muscular dystrophy type 2A: The yield and the pitfalls
  157. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy
  158. Impaired autophagy affects acid α-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II
  159. Burden, professional support, and social network in families of children and young adults with muscular dystrophies
  160. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E
  161. Spectrum of metabolic myopathies
  162. Redefining phenotypes associated with mitochondrial DNA single deletion
  163. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population
  164. Familial polyglucosan body myopathy with unusual phenotype
  165. Ergebnisse und Empfehlungen des 7th European Hypoxia Symposiums 2014
  166. Prevalence of Asymptomatic Vertebral Fractures in Late-Onset Pompe Disease
  167. Prevention of cardiomyopathy in Duchenne muscular dystrophy
  168. Primary coenzyme Q10 deficiency presenting as fatal neonatal multiorgan failure
  169. Erratum: Measurement of the absolute branching fractions forDs−→
  170. The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases
  171. Dominant muscular dystrophy with a novelSYNE1gene mutation
  172. Impaired copper and iron metabolism in blood cells and muscles of patients affected by copper deficiency myeloneuropathy
  173. T.P.18
  174. G.O.7
  175. G.P.251
  176. Genotype-phenotype correlation in Pompe disease, a step forward
  177. Skeletal Muscle Satellite Cells in Amyotrophic Lateral Sclerosis
  178. Muscle atrophy, ubiquitin-proteasome, and autophagic pathways in dysferlinopathy
  179. Improving the knowledge of amyotrophic lateral sclerosis genetics: novel SOD1 and FUS variants
  180. Gender difference in limb-girdle muscular dystrophy: a muscle fiber morphometric study in 101 patients
  181. CIR-Myo News: Proceedings of the 2014 Spring Padua Muscle Days
  182. Neurologia Clinica
  183. Myoclonus in mitochondrial disorders
  184. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy
  185. Genetic Neuromuscular Disorders
  186. Limb-Girdle Muscular Dystrophy Type 2F
  187. Limb-Girdle Muscular Dystrophy Type 2N
  188. Limb-Girdle Muscular Dystrophy Type 2K
  189. Amyotrophic Lateral Sclerosis Type 1
  190. Ataxia-Telangiectasia, Louis-Bar Syndrome
  191. Glycogenosis Type 3, Cori-Forbes Disease
  192. Niemann-Pick Disease Type C1
  193. Myotonic Dystrophy Type 2, Proximal Myotonic Myopathy
  194. Spastic Ataxia, Charlevoix-Saguenay Type
  195. Multiple Acyl-CoA Dehydrogenase Deficiency
  196. Systemic Primary Carnitine Deficiency
  197. Kearns-Sayre Syndrome
  198. Brody Disease
  199. Limb-Girdle Muscular Dystrophy Type 2C
  200. Charcot-Marie-Tooth Neuropathy with Pyramidal Features
  201. Myotonic Dystrophy Type 1, Steinert Disease
  202. Hereditary Inclusion Body Myopathy Type 2
  203. Autophagy in Natural History and After ERT in Glycogenosis Type II
  204. Limb-Girdle Muscular Dystrophies
  205. Friedreich’s Ataxia
  206. Limb-Girdle Muscular Dystrophy Type 1B
  207. The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender?
  208. A New Self-Report Quality of Life Questionnaire for Children With Neuromuscular Disorders
  209. “I have got something positive out of this situation”: psychological benefits of caregiving in relatives of young people with muscular dystrophy
  210. Muscle atrophy in Limb Girdle Muscular Dystrophy 2A: a morphometric and molecular study
  211. Erratum: Measurement of theD*(2010)...
  212. Erratum: Measurement of theD*(2010)...
  213. P.5.7 Limb-girdle muscular dystrophy type 2E: Clinical, genetic and histopathological features of 27 European patients
  214. P.17.5 Analysis of motor assessments administered at treatment initiation for patients in the pompe registry
  215. P.5.10 Clinical and ultrastructural changes in transportinopathy
  216. P.12.2 Dominant distal myopathy due to slow channelopathy
  217. P.6.4 Salbutamol tolerability and efficacy in adult type III SMA patients: Results of a multicentric, molecular and clinical, double-blind, placebo-controlled study
  218. Large scale genotype–phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy
  219. Enzyme Replacement Therapy Improves Respiratory Outcomes in Patients with Late-Onset Type II Glycogenosis and High Ventilator Dependency
  220. Next-Generation Sequencing Identifies Transportin 3 as the Causative Gene for LGMD1F
  221. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
  222. Therapeutic advances in the management of Pompe disease and other metabolic myopathies
  223. Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation
  224. Clinical phenotype, muscle MRI and muscle pathology of LGMD1F
  225. EFNS review on the role of muscle biopsy in the investigation of myalgia
  226. Publisher’s Note: Search for di-muon decays of a low-mass Higgs boson in radiative decays of theΥ(1S...
  227. Erratum: Branching fraction measurements of the color-suppressed decaysB¯0
  228. New treatments for myasthenia: a focus on antisense oligonucleotides
  229. Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy
  230. Autonomic regulation in muscular dystrophy
  231. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis
  232. Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship
  233. Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
  234. Targeted array comparative genomic hybridization – A new diagnostic tool for the detection of large copy number variations in nemaline myopathy-causing genes
  235. Telethon Network of Genetic Biobanks: a key service for diagnosis and research on rare diseases
  236. Ultrastructural changes in LGMD1F
  237. Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases
  238. Fatigue in muscular dystrophies
  239. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients
  240. Measuring quality of life impairment in skeletal muscle channelopathies
  241. Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study
  242. S.P.24 24-Hour Holter ECG in type II and III SMA
  243. D.O.3 Next generation sequencing applications are ready for genetic diagnosis of muscular dystrophies
  244. D.P.13 Targeted array CGH analysis of the nebulin gene: Identification of large deletions causing nemaline myopathy
  245. TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle
  246. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy
  247. Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for “double trouble” overlapping syndromes
  248. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells
  249. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII)
  250. New motor outcome function measures in evaluation of Late‐Onset Pompe disease before and after enzyme replacement therapy
  251. Erratum: Search forCPviolation in the decay
  252. Cardiomyopathy in patients with POMT1-related congenital and limb-girdle muscular dystrophy
  253. An intronic mutation causes severe LGMD2A in a large inbred family belonging to a genetic isolate in the Alps
  254. Large-Scale Population Analysis Challenges the Current Criteria for the Molecular Diagnosis of Fascioscapulohumeral Muscular Dystrophy
  255. Atypical onset in a series of 122 cases with FacioScapuloHumeral Muscular Dystrophy
  256. Calpain 3 is important for muscle regeneration: Evidence from patients with limb girdle muscular dystrophies
  257. Publisher’s Note: Observation of the baryonicBdecay
  258. CAG repeat length in androgen receptor gene is not associated with amyotrophic lateral sclerosis
  259. Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues
  260. Neuromuscular diseases: advances in therapy and diagnosis
  261. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years
  262. Publisher’s Note: Study of radiative bottomonium transitions using converted photons [Phys. Rev. DPRVDAQ1550-799884, 072002 (2011)]
  263. Optimization of respiratory chain enzymatic assays in muscle for the diagnosis of mitochondrial disorders
  264. Enzyme Replacement Therapy for Pompe Disease
  265. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency
  266. P2.27 Full exome resequencing by next generation sequencing (NGS) combined with chip analysis for the genetic testing of unclassified myopathic patients
  267. Clinical and molecular characterization of limb-girdle muscular dystrophy due to LAMA2 mutations
  268. Diagnostic Approach to Pauci- or Asymptomatic hyperCKemia
  269. Parkinson-like features in ALS with predominant upper motor neuron involvement
  270. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion
  271. Study of Muscle Autophagy and Atrophy Markers in Different Phenotypes of Pompe Disease
  272. Outcome Measures in Juvenile/Adult GSDII Cases
  273. Pompe Disease Diagnosis, Treatment, and Outcomes in Italy: Pompe Disease Registry Data from Italy Compared with the Rest-of-World
  274. Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations
  275. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland
  276. Cognitive profile and MRI findings in limb-girdle muscular dystrophy 2I
  277. Erratum to: Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies
  278. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency
  279. Diagnosis and Management of Autoimmune Myasthenia Gravis
  280. A type of Amyotrophic Lateral Sclerosis or Lou Gehrig disease has genetic biomarkers
  281. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy
  282. Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies
  283. Abnormal expression of dysferlin in skeletal muscle and monocytes supports primary dysferlinopathy in patients with one mutated allele
  284. P2.32 The frequency of myotonic dystrophy type 2 (DM2) and type 1 (DM1) mutations in the population
  285. Retrospective study on PET–SPECT imaging in a large cohort of myotonic dystrophy type 1 patients
  286. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report
  287. A review of what is known about fatty acids inherited defects
  288. Transcriptional and translational effects of intronic CAPN3 gene mutations
  289. Right hemisphere dysfunction and emotional processing in ALS: an fMRI study
  290. The Role of Ultrastructural Examination in Storage Diseases
  291. Psychopathological features and suicidal ideation in amyotrophic lateral sclerosis patients
  292. Metabolic myopathies: the challenge of new treatments
  293. A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score
  294. Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells
  295. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia
  296. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases
  297. Subacute sensory ataxia and optic neuropathy with thiamine deficiency
  298. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2
  299. MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies
  300. This represents an accurate description of disease course in two main LGMD
  301. Quality of life and motor impairment in ALS: Italian validation of ALSAQ
  302. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients
  303. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy
  304. TDP-43 in skeletal muscle of patients affected with amyotrophic lateral sclerosis
  305. Cardiomyopathy in a patient with limb-girdle muscular dystrophy type 2D: Pathomorphological aspects
  306. Natural history of upper motor neuron-dominant ALS
  307. G.P.15.08 High genetic variability in European population: The FSHD complex puzzle
  308. G.P.4.07 Skeletal muscle regeneration in amyotrophic lateral sclerosis
  309. G.P.15.09 Unexpected high percentage of asymptomatic subjects carrying the FSHD molecular defect: Which factors contribute to the disease mechanism?
  310. Epidemiology of ALS in Padova district, Italy, from 1992 to 2005
  311. Publisher’s Note: Exclusive initial-state-radiation production of theDD¯,
  312. Reliability of the North Star Ambulatory Assessment in a multicentric setting
  313. Carnitine deficiency
  314. TARDBP(TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations
  315. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample
  316. Progress in enzyme replacement therapy in glycogen storage disease type II
  317. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes
  318. Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy
  319. Sarcolemmal Neuronal Nitric Oxide Synthase Defect in Limb-Girdle Muscular Dystrophy: An Adverse Modulating Factor in the Disease Course?
  320. Two novel cosegregating mutations in tRNAMet and COX III, in a patient with exercise intolerance and autoimmune polyendocrinopathy
  321. Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2)
  322. Emotional Lability in MND: Relationship to cognition and psychopathology and impact on caregivers
  323. Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables
  324. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR
  325. Transcriptional behavior of DMD gene duplications in DMD/BMD males
  326. Chapter 31 Muscular dystrophy
  327. Standards of Care for Duchenne Muscular Dystrophy: Brief Treat-NMD Recommendations
  328. TDP-43 in skeletal muscle of patients affected with amyotrophic lateral sclerosis
  329. Recent advances and current clinical perspectives in the diagnosis and treatment of glycogenosis type II
  330. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A
  331. Sphingomonas paucimobilis associated with localised calf myositis
  332. D.P.1.02 A robust tool to quantify disability in patients affected by facioscapulohumeral muscular dystrophy
  333. D.P.4.07 In vitro study of DM1 primary myotubes
  334. D.P.1.04 Size and number of D4Z4 alleles play a role in FSHD phenotype
  335. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2
  336. A novel deletion in the GTPase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function
  337. Inhibition of Proteasome Activity Promotes the Correct Localization of Disease-Causing α-Sarcoglycan Mutants in HEK-293 Cells Constitutively Expressing β-, γ-, and δ-Sarcoglycan
  338. S9.7 Dominant optic atrophy caused by a novel OPA1 mutation: Disruption of the mitochondrial network with preserved bioenergetics
  339. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients
  340. Erratum: Thee+e−→2
  341. Publisher’s Note: Erratum: Measurement of Branching Fractions and Mass Spectra ofB→Kππ
  342. Erratum: Measurement of Branching Fractions and Mass Spectra ofB→Kππγ
  343. Clinical and genetic characterization of Chanarin–Dorfman syndrome
  344. Amyotrophic Lateral Sclerosis With Ragged-Red Fibers
  345. Cardioembolic stroke in Danon disease
  346. Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency
  347. Publisher’s Note: Search for the rare charmless hadronic decayB+→a0<...
  348. Publisher’s Note: Search for the rare charmless hadronic decayB+→a0<...
  349. Muscle histopathology in upper motor neuron-dominant amyotrophic lateral sclerosis
  350. Spinal and bulbar muscular atrophy: Skeletal muscle pathology in male patients and heterozygous females
  351. Nutritional Recommendations for Patients with Glycogen Storage Disease Type II
  352. Dysferlinopathies
  353. Biochemical and ultrastructural evidence of endoplasmic reticulum stress in LGMD2I
  354. Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A
  355. Detection of an unstable non-coding tandem repeat in the ZNF291 gene
  356. M.P.5.06 Protocol for enzyme replacement therapy in late-onset glycogenosis type II (GSDII)
  357. G.P.14.15 Brain involvement in myotonic dystrophy type 2
  358. G.P.15.16 Importance of self-report in pediatric quality of life assessment: Experience with the SOLE questionnaire in children with neuromuscular disorders
  359. G.P.3.07 Intronic conserved non-coding sequences (CNSs) as a tool to detect non-coding RNAs (ncRNAs) and putative regulatory motifs within the dystrophin gene
  360. G.P.8.06 Limb-girdle muscular dystrophies: DNA test following protein test or not?
  361. M.P.4.12 Molecular analysis of the ABHD5 gene in Italian patients with multisystem triglyceride storage disease (Chanarin-Dorfman syndrome)
  362. G.P.7.02 Multicenter study on occurrence of auditory impairment in facioscapulohumeral muscular dystrophy
  363. G.P.15.15 The SOLE questionnaire: Development and validation of a new instrument for measuring quality of life in children with neuromuscular disorders
  364. G.P.4.07 Relation between LGMD2B progression and physical activity
  365. Association Between Human Polymorphic DNA Markers and Hypoxia Adaptation in Sherpa Detected by a Preliminary Genome Scan
  366. In common dystrophy, the hearing was impaired
  367. Late-onset GSDII with novel GAA gene mutation
  368. Myelo-optico-neuropathy in copper deficiency occurring after partial gastrectomy
  369. Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients
  370. MYH7 gene mutation in myosin storage myopathy and scapulo-peroneal myopathy
  371. Risk Prediction for Clinical Phenotype in Myotonic Dystrophy Type 1: Data from 2,650 Patients
  372. Childhood dermatomyositis associated with intracranial tumor and liver cysts
  373. The role of corticosteroids in muscular dystrophy: A critical appraisal
  374. Disorders of lipid metabolism
  375. Erratum: Dalitz-plot analysis of the decaysB±→K±
  376. Expression profiling characterization of laminin α-2 positive MDC
  377. High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm
  378. Muscle protein analysis in the detection of heterozygotes for recessive limb girdle muscular dystrophy type 2B and 2E
  379. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders
  380. A truncation in the RYR1 gene associated with central core lesions in skeletal muscle fibres
  381. Exploring mental status in Friedreich's ataxia: a combined neuropsychological, behavioral and neuroimaging study
  382. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations
  383. Erratum: Determination of|Vub
  384. McArdle disease: the mutation spectrum ofPYGMin a large Italian cohort
  385. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
  386. Gene Expression Analysis in Myotonic Dystrophy: Indications for a Common Molecular Pathogenic Pathway in DM1 and DM2
  387. Generalized Lysosome-Associated Membrane Protein-2 Defect Explains Multisystem Clinical Involvement and Allows Leukocyte Diagnostic Screening in Danon Disease
  388. Coordinated and reversible reduction of enzymes involved in terminal oxidative metabolism in skeletal muscle mitochondria from a riboflavin-responsive, multiple acyl-CoA dehydrogenase deficiency patient
  389. Intronic breakpoint definition and transcription analysis in DMD/BMD patients with deletion/duplication at the 5′ mutation hot spot of the dystrophin gene
  390. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb–MyoD pathways in muscle regeneration
  391. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1
  392. Identification of 45 novel mutations in the nebulin gene associated with autosomal recessive nemaline myopathy
  393. A pilot trial with clenbuterol in amyotrophic lateral sclerosis
  394. Facioscapulohumeral Muscular Dystrophy and Occurrence of Heart Arrhythmia
  395. Clinical and Molecular Characterization of Patients With Limb-Girdle Muscular Dystrophy Type 2I
  396. Co-segregation of LMNA and PMP22 gene mutations in the same family
  397. Decreased expression of DMPK: correlation with CTG repeat expansion and fibre type composition in myotonic dystrophy type 1
  398. Decorin and biglycan expression is differentially altered in several muscular dystrophies
  399. Extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes
  400. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10-responsive condition
  401. Dominant LMNA mutations can cause combined muscular dystrophy and peripheral neuropathy
  402. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy
  403. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures
  404. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism
  405. A novel out-of-frame mutation in the neurofilament light chain gene ( NEFL) does not result in Charcot-Marie-Tooth disease type 2E
  406. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia
  407. Correlating phenotype and genotype in the periodic paralyses
  408. Publisher's Note: Search for the Rare Leptonic DecayB+→μ+
  409. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy
  410. LAMA2loss-of-function mutation in a girl with a mild congenital muscular dystrophy
  411. Large-scale disruption of microtubule pathways in morphologically normal human spastin muscle
  412. Molecular and muscle pathology in a series of caveolinopathy patients
  413. Molecular diagnosis in LGMD2A: Mutation analysis or protein testing?
  414. Motor function-muscle strength relationship in spinal muscular atrophy
  415. Decreased Fatty Acid β-Oxidation in Riboflavin-Responsive, Multiple Acylcoenzyme A Dehydrogenase-Deficient Patients Is Associated with an Increase in Uncoupling Protein-3
  416. Loss of Calpain-3 Autocatalytic Activity in LGMD2A Patients with Normal Protein Expression
  417. two families with spastic paraplegia are described
  418. Role of Gabapentin in Spinal Muscular Atrophy
  419. Acetylcholinesterase activity is affected by stress conditions in Paracentrotus lividus coelomocytes
  420. Novel sarcoglycan gene mutations in a large cohort of Italian patients
  421. LGMD2E patients risk developing dilated cardiomyopathy
  422. Memory deficits and retrieval processes in ALS1
  423. Cerebellar ataxia and coenzyme Q10 deficiency
  424. Phenotype modulators in myophosphorylase deficiency
  425. Clinical and molecular study in congenital muscular dystrophy with partial laminin ?2 (LAMA2) deficiency
  426. Neuromuscular Diseases, Expert Clinicians Views
  427. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray
  428. Muscle pathology in dysferlin deficiency
  429. Investigating the Mechanism of Chromosomal Deletion: Characterization of 39 Deletion Breakpoints in Introns 47 and 48 of the Human Dystrophin Gene
  430. Investigating the Mechanism of Chromosomal Deletion: Characterization of 39 Deletion Breakpoints in Introns 47 and 48 of the Human Dystrophin Gene
  431. Publisher’s Note: Measurement of theB0Lifetime with Partially Reconstructed
  432. Integrin α7β1 in Muscular Dystrophy/Myopathy of Unknown Etiology
  433. Defective assembly of sarcoglycan complex in patients with β-sarcoglycan gene mutations. Study of aneural and innervated cultured myotubes
  434. Detection of HTLV-I tax-rex and pol Gene Sequences of Thymus Gland in a Large Group of Patients With Myasthenia Gravis
  435. Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis
  436. Validation of internationally agreed criteria to diagnose Amyotrophic Lateral Sclerosis.
  437. Changes in the ultrastructure and glycoproteins of the cyst wall of Colpoda cucullus during resting encystment
  438. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy
  439. A new mutation in a family with cold-aggravated myotonia disrupts Na+ channel inactivation
  440. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy
  441. Caspase 3 Expression Correlates With Skeletal Muscle Apoptosis in Duchenne and Facioscapulo Human Muscular Dystrophy. A Potential Target for Pharmacological Treatment?
  442. Heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy: molecular and biochemical defects on cardiac and skeletal muscle
  443. Validity of hospital discharge diagnoses for the assessment of the prevalence and incidence of amyotrophic lateral sclerosis
  444. New therapies in muscular dystrophies
  445. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents
  446. Correlation of clinical function and muscle CT scan images in limb-girdle muscular dystrophy
  447. A novel laminin  2 isoform in severe laminin  2 deficient congenital muscular dystrophy
  448. Hereditary spastic paraplegia associated with peripheral neuropathy: a distinct clinical and genetic entity
  449. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy
  450. Acute Quadriplegic Myopathy in a 17-Month-Old Boy
  451. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy
  452. Private ?- and ?-sarcoglycan gene mutations: Evidence of a founder effect in Northern Italy
  453. Riboflavin therapy
  454. A Stop-Codon Mutation in the Human mtDNA Cytochrome c Oxidase I Gene Disrupts the Functional Structure of Complex IV
  455. Cognitive impairment and (CTG)n expansion in myotonic dystrophy patients
  456. Could Utrophin Rescue the Myocardium of Patients with Dystrophin Gene Mutations?
  457. Infantile lipid storage myopathy with nocturnal hypoventilation shows abnormal low-affinity muscle carnitine uptake in vitro
  458. Prenatal diagnosis in a family affected with β-sarcoglycan muscular dystrophy
  459. Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression
  460. Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients
  461. Regeneration in sarcoglycanopathies: expression studies of sarcoglycans and other muscle proteins
  462. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations
  463. Clinical and neuroimaging study of central nervous system in congenital myotonic dystrophy
  464. Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population
  465. The clinical spectrum of sarcoglycanopathies
  466. Cardiac transplantation in a Duchenne muscular dystrophy carrier
  467. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy
  468. Steroids in muscular dystrophy: where do we stand?
  469. Laminin  2 muscular dystrophy: Genotype/phenotype studies of 22 patients
  470. Homozygous ?-sarcoglycan mutation in two siblings: One asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patient
  471. Radiological evidence of subclinical dysphagia in motor neuron disease
  472. Positive correlation of CTG expansion and pharyngoesophageal alterations in myotonic dystrophy patients
  473. Congenital Muscular Dystrophy with Partial Merosin Deficiency and Late Onset Epilepsy
  474. Mutations of the same sequence of the myelin P0 gene causing two different phenotypes
  475. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations.
  476. Increased aldosterone levels in acute mountain sickness at Capanna Regina Margherita
  477. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients
  478. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: Effect of propionyl-L-carnitine
  479. RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance.
  480. Mutations in the Sarcoglycan Genes in Patients with Myopathy
  481. Genotype-phenotype correlations of DHP receptor α1-subunit gene mutations causing hypokalemic periodic paralysis
  482. Novel mutations and polymorphisms in the human dystrophin gene detected by double-strand conformation analysis
  483. Novel mutations and polymorphisms in the human dystrophin gene detected by double‐strand conformation analysis
  484. Myocardial Involvement Is Very Frequent Among Patients Affected With Subclinical Becker's Muscular Dystrophy
  485. Prediction of myotonic dystrophy clinical severity based on the number of intragenic [CTG]n trinucleotide repeats
  486. Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy
  487. Myotonia and the muscle chloride channel: Dominant mutations show variable penetrance and founder effect
  488. Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy
  489. Esophageal motor function in patients with myotonic dystrophy
  490. Prognostic factors in mild dystrophinopathies
  491. Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: Threshold effect for deletion size?
  492. α-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations
  493. Discordant clinical outcome in type III spinal muscular atrophy sibships showing the same deletion pattern
  494. Molecular characterization of myophosphorylase deficiency in a group of patients from Northern Italy
  495. Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy
  496. Residual muscle cytochrome c oxidase activity accounts for submaximal exercise lactate threshold in chronic progressive external ophthalmoplegia
  497. X‐inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X‐linked determinant
  498. X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant
  499. A Point Mutation in the 5' Splice Site of the Dystrophin Gene First Intron Responsible for X-Linked Dilated Cardiomyopathy
  500. Skeletal muscle sarcoplasmic reticulum phenotype in myotonic dystrophy
  501. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy
  502. Correction: Corrigendum: β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex
  503. Hereditary protein C deficiency associated with riboflavin-responsive lipid storage myopathy
  504. Motor Neuron Disease in the Padua District of Italy: An Epidemiological Study
  505. β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex
  506. Dystrophin-positive fibers in duchenne dystrophy: Origin and correlation to clinical course
  507. Survival Motor-Neuron Gene Transcript Analysis in Muscles from Spinal Muscular-Atrophy Patients
  508. Audit of care of acute inflammatory polyradiculoneuropathy in Italy
  509. MtDNA Mutations Associated with Leber′s Hereditary Optic Neuropathy: Studies on Cytoplasmic Hybrid (Cybrid) Cells
  510. Prevalence of unsuspected myopathy in infants presenting for clubfoot surgery
  511. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: Evidence for failure of dystrophin production in dystrophin-competent myonuclei
  512. Neonatal spinal muscular atrophy with diaphragmatic paralysis is unlinked to 5q11.2-q13.
  513. Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 repeats
  514. Prenatal diagnosis in congenital muscular dystrophy
  515. Postzygotic instability of the myotonic dystrophy p[AGC]n repeat supported by larger expansions in muscle and reduced amplifications in sperm
  516. Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy
  517. Myophosphorylase deficiency affects muscle mitochondrial respiration as shown by 31P-MR spectroscopy in a case with associated multifocal encephalopathy
  518. Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation
  519. Divergence of Central Nervous System Involvement in 2 Italian Sisters with Congenital Muscular Dystrophy: A Clinical and Neuroradiological Follow-Up
  520. Frequency of Duplication at 17p11.2 in Families of Northeast Italy with Charcot-Marie-Tooth Disease Type 1
  521. Non-radioactive detection of 17p11.2 duplication in CMT1A: a study of 78 patients.
  522. A study on duplications of the dystrophin gene: Evidence of a geographical difference in the distribution of breakpoints by intron
  523. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: Characterization of sub-clinical phenotypes
  524. Deflazacort in Duchenne dystrophy: Study of long-term effect
  525. Preface
  526. Prevalent cardiac involvement in dystrophin Becker type mutation
  527. Male Hypogonadism in Myotonic Dystrophy is Related to (Ctg)N Triplet Mutation
  528. Absence of dystrophin and spectrin in regenerating muscle fibers from Becker dystrophy patients
  529. Deflazacort in Duchenne dystrophy: Study of long-term effect
  530. Occurrence of two different intragenic deletions in two male relatives affected with Duchenne muscular dystrophy
  531. Single Muscle Fibre Analyses in 2 Brothers with Succinate Dehydrogenase Deficiency
  532. Cardiac involvement in becker muscular dystrophy
  533. Expression of muscle-type phosphorylase in innervated and aneural cultured muscle of patients with myophosphorylase deficiency.
  534. (CTG)n Triplet Mutation and Phenotype Manifestations in Myotonic Dystrophy Patients
  535. Multifactorial study of inflammatory myopathies. Report of 29 cases
  536. Dystrophin-positive myotubes in innervated muscle cultures from Duchenne and Becker muscular dystrophy patients
  537. Reappraisal of the Incidence Rate of Duchenne and Becker Muscular Dystrophies on the Basis of Molecular Diagnosis
  538. Melas syndrome was diagnosed in two families
  539. Further evidence of a duplication in 17p11.2 in families with recurrence of HMSN Ia (Charcot-Marie-Tooth neuropathy type Ia)
  540. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts.
  541. Dystrophinopathy in isolated cases of myopathy in females
  542. MELAS: Clinical features, biochemistry, and molecular genetics
  543. Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients.
  544. Cognitive and psychiatric evaluation of 40 patients with myotonic dystrophy
  545. Clinical and Biochemical Aspects of Carnitine Deficiency and Insufficiency: Transport Defects and Inborn Errors of β-Oxidation
  546. Prevalence of dystrophin-positive fibers in 85 duchenne muscular dystrophy patients
  547. Variability of the expression of muscle mitochondrial damage in ocular mitochondrial myopathy
  548. Epidemiology of Spinal Muscular Atrophies in a Sample of the Italian Population
  549. l-Carnitine uptake in differentiating human cultured muscle
  550. Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of duchenne muscular dystrophy
  551. Muscle carnitine deficiency in patients with severe peripheral vascular disease.
  552. Congenital muscular dystrophy: brain alterations in an unselected series of Western patients.
  553. MYOTONIC DYSTROPHY
  554. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial
  555. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy
  556. 7 Defects of fatty-acid oxidation in muscle
  557. Enormous dystrophin in a patient with Becker muscular dystrophy
  558. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q
  559. Liver fatty acid-binding protein in two cases of human lipid storage
  560. Serum Lipids, Lipoprotein Analysis and Apoprotein A-I, A-II and B Levels in Friedreich’s Ataxia
  561. Intellectual Impairment and Cognitive Evoked Potentials in Myotonic Dystrophy
  562. Type 1 fiber abnormalities in skeletal muscle of patients with hypertrophic and dilated cardiomyopathy: Evidence of subclinical myogenic myopathy
  563. CROSS-REACTIVE PROTEIN IN DUCHENNE MUSCLE
  564. Improved diagnosis of Becker muscular dystrophy by dystrophin testing
  565. Muscle glycerol kinase in Duchenne dystrophy and glycerol kinase deficiency
  566. The role of life events in the myasthenia gravis outcome: a one-year longitudinal study
  567. Myosin heavy chain composition of muscle fibers in spinal muscular atrophy
  568. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
  569. Psychiatric disturbances associated with myasthenia gravis
  570. The natural history of cardiac involvement in myotonic dystrophy: An eight-year follow-up in 17 patients
  571. Glucose and ketone body turnover in carnitine-palmitoyl-transferase deficiency
  572. Exercise-induced recurrent myoglobinuria: Defective activity of inner carnitine palmitoyltransferase in muscle mitochondria of two patients
  573. Population data on benign and severe forms of X-linked muscular dystrophy
  574. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency
  575. Friedreich's disease: V. Variant form with vitamin E deficiency and normal fat absorption
  576. Genetic epidemiology of myotonic dystrophy
  577. Myotonic dystrophy and chromosome translocation segregating in the same family
  578. Toxic myopathy induced by industrial minerals oils: Clinical and histopathological features
  579. Childhood encephalomyopathy with cytochrome c oxidase deficiency, ataxia, muscle wasting, and mental impairment
  580. Malonyl-CoA Abnormal Inhibition of Residual Enzyme Activity in Carnitine Palmitoyltransferase Deficiency
  581. Sensory, Motor, and Autonomic Neuropathy in Patients with Multiple Symmetric Lipomatosis
  582. Carnitine deficiency, organic acidemias, and Reye's syndrome
  583. Familial neuromuscular disease with tubular aggregates
  584. Tubular aggregates: Sarcoplasmic reticulum origin, calcium storage ability, and functional implications
  585. Carnitine and acyltransferase in experimental neurogenic atrophies: changes with treatment
  586. Myoglobinuria and carnitine palmityltransferase (CPT) deficiency: Studies with malonyl-CoA suggest absence of only CPT-II
  587. Incidence and Risk Factors of Motor Neuron Disease in the Venice and Padua Districts of Italy, 1972–1979
  588. Carnitine, carnitine acyltransferases, and rat brain function
  589. Autoimmune neuromuscular disease induced by a preparation of choline acetyltransferase
  590. Peroneal muscular atrophy with ataxia and partial myoclonic epilepsy
  591. Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy
  592. Carnitine palmityl transferase deficiency: Clinical variability, carrier detection, and autosomal-recessive inheritance
  593. Myopathological Findings in Progressive Myoclonus Epilepsy
  594. Systemic Carnitine Deficiency — A Treatable Inherited Lipid-Storage Disease Presenting as Reye's Syndrome
  595. Plasma and Urine Carnitine Levels During Development
  596. Abnormal myomuscular junctions and AChE in a congenital neuromuscular disease
  597. Duchenne muscular dystrophy
  598. Free and acyl-carnitines in human milk and colostrum: 89
  599. Multisystem triglyceride storage disorder with impaired long-chain fatty acid oxidation
  600. Assessment of the value of thymic scan in myasthenia gravis
  601. Carnitine deficiency: Acute postpartum crisis
  602. CARNITINE DEFICIENCY INDUCED DURING HÆMODIALYSIS
  603. Duchenne muscular dystrophy
  604. DUCHENNE CARRIER DETECTION
  605. Carnitine deficiency of skeletal muscle: Report of a treated case
  606. DUCHENNE CARRIER DETECTION
  607. Lipid storage myopathies
  608. CARNITINE DEFICIENCY
  609. Geographic distribution of hereditary myopathies in northeast Italy
  610. Mitochondria-Lipid-Glycogen (MLG) Disease of Muscle
  611. Subcellular distribution of acid and neutral α-glucosidases in normal, acid maltose deficient, and myophosphorylase deficient human skeletal muscle
  612. Carnitine Deficiency of Human Skeletal Muscle with Associated Lipid Storage Myopathy: A New Syndrome
  613. Adult Acid Maltase Deficiency
  614. Comparative Study of Acid Maltase Deficiency
  615. Developmental patterns of LDH isozymes in fast and slow muscles of the rat
  616. Early ultrastructural and biochemical changes in muscle in dystrophia myotonica
  617. Enzymes of the glycogen cycle and glycolysis in various human neuromuscular disorders.